A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Saved in:
| Title: | A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. |
|---|---|
| Authors: | Weinblatt, Michael E.1 mweinblatt@partners.org, Bingham, Clifton O.2, Burmester, Gerd‐Rüdiger3, Bykerk, Vivian P.4, Furst, Daniel E.5, Mariette, Xavier6, van der Heijde, Désirée7, van Vollenhoven, Ronald8, VanLunen, Brenda9, Ecoffet, Cécile10, Cioffi, Christopher9, Emery, Paul11 |
| Source: | Arthritis & Rheumatology. Oct2017, Vol. 69 Issue 10, p1937-1948. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
